✨ Free AI Report
Aquestive Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aquestive Therapeutics, Inc.
Company Research

Aquestive Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Aquestive is a pharmaceutical company advancing medicines through innovative science and delivery technologies, developing orally administered products to deliver complex molecules as novel alternatives to invasive an...

Analyst-debate audio for Aquestive Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Aquestive Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Aquestive's first-in-class Anaphylm program faces near-term regulatory hurdles but Q3 2026 resubmission and international...

Read the full analyst-debate transcript →
Industry Pharmaceutical/Specialty Pharmaceuticals (Allergy/Emergency Medicine)
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aquestive Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Aquestive Therapeutics, Inc. Overview

Pro stress-test →

Aquestive is a pharmaceutical company advancing medicines through innovative science and delivery technologies, developing orally administered products to deliver complex molecules as novel alternatives to invasive and inconvenient standard therapies. The company is heavily focused on Anaphylm™, a first-in-class oral epinephrine sublingual film for treating anaphylaxis, after receiving an FDA Complete Response Letter in January 2026 with addressable deficiencies.

Strategic Profile

Pro stress-test →

Aquestive operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, headquartered in New Jersey with U.S.-based manufacturing in Indiana, and is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents. The company reported approximately $120 million cash as of December 31, 2025 and plans regulatory submissions in Canada, Europe, and the UK in 2026.

Competitive Landscape

Pro stress-test →

If approved, Anaphylm would be the first and only oral medication for rescue treatment of severe allergic reactions. Current competitors remain limited to epinephrine auto-injectors (EpiPen, Auvi-Q) and other conventional injection-based therapies. The company's differentiation centers on oral delivery convenience, portability, and ease of use compared to injection-based solutions.

Industry Context

Aquestive Therapeutics, Inc. operates in Pharmaceutical/Specialty Pharmaceuticals (Allergy/Emergency Medicine).

Key facts

Headquarters: Warren, New Jersey · Revenue: $44–$50M guidance 2025

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aquestive Therapeutics, Inc..

  • The company estimates resubmission in Q3 2026, assuming completion of the HF and PK studies, and plans to request rapid review by the FDA.
  • If approved by the FDA, Anaphylm would be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Appointed Dr. Matthew Greenhawt as Chief Medical Officer to support Anaphylm NDA resubmission
  • February 2026Presented clinical data at AAAAI Annual Meeting showing Anaphylm achieved clinically relevant epinephrine concentrations without diastolic blood pressure dip
  • +1 moreTrack every material event for Aquestive Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Aquestive Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

EpiPen (epinephrine autoinjector)Established auto-injector for anaphylaxis rescue; incumbent market standard→Auvi-Q (epinephrine autoinjector)Compact epinephrine autoinjector alternative to EpiPen→

Compare Aquestive Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aquestive Therapeutics, Inc. operates in Pharmaceutical/Specialty Pharmaceuticals (Allergy/Emergency Medicine). See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical/Specialty Pharmaceuticals (Allergy/Emergency Medicine) research →
NEW · MCP server

Ask your AI assistant about Aquestive Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aquestive Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Aquestive Therapeutics, Inc. do this quarter?”
“Is Aquestive Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aquestive Therapeutics, Inc. do?+
Aquestive is a pharmaceutical company advancing medicines through innovative science and delivery technologies, developing orally administered products to deliver complex molecules as novel alternatives to invasive an...
What is Aquestive Therapeutics, Inc.'s Cyborg Score?+
Aquestive Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aquestive Therapeutics, Inc.'s main competitors?+
Named competitors include EpiPen (epinephrine autoinjector), Auvi-Q (epinephrine autoinjector). The full competitive landscape is in the AskCyborg report.
How can I get the full Aquestive Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aquestive Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aquestive Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Elanco Animal Health Incorporated7Nanexa AB7SIGA Technologies, Inc.3Boundless Bio, Inc.